RNS Number : 0287U

Silence Therapeutics PLC

30 March 2021

Silence Therapeutics Publication of Annual Report

30 March 2021

LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN (" Silence " or " the Company "), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that its annual report and financial statements for the year ended 31 December 2020 ("Annual Report and Accounts") are available for download on the Company's website www.silence-therapeutics.com and linked here. The Annual Report and Accounts will be posted to shareholders, who have elected to opt out on receiving electronic communications, on or before 26 April 2021.


 Silence Therapeutics plc                                Tel: +1 (646) 637-3208 
  Gem Hopkins, Head of IR and Corporate Communications 
  Investec Bank plc (Nominated Adviser and                Tel: +44 (0) 20 
   Broker)                                                 7597 5970 
   Daniel Adams/Gary Clarence 
 European PR                                             Tel: +44 (0) 20 
  Consilium Strategic Communications                      3709 5700 
  Mary-Jane Elliott/ Angela Gray / Chris Welsh 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD(TM) platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

March 30, 2021 13:13 ET (17:13 GMT)